Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (2)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2019 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.

Related

Vinge advises on the sale of Compab to Tången

 Vinge has advised the owners of Compab Energiteknik in connection with the sale of 80 per cent of the shares to Tången Industrikapital. Compab, which has a turnover of approximately SEK 100 million, sells, installs and services, amongst other things, steam and hot-water boilers as well as burners for the industrial sector.
October 26, 2026

Vinge advises Capio on the acquisition of Rehabhotellet Sthlm AB

 Rehabhotellet i Sthlm AB provides advanced home healthcare and specialized inpatient palliative care within the Stockholm Region.
October 26, 2026

Vinge has advised AIP Management on the acquisition of the Överturingen wind farm

Vinge has advised AIP Management, an investor specialising in energy and climate transition infrastructure, in connection with the acquisition of an onshore wind farm in Överturingen in central Sweden.
October 22, 2026